BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 29637585)

  • 1. Impact of HBV genotype and mutations on HBV DNA and qHBsAg levels in patients with HBeAg-negative chronic HBV infection.
    Kuhnhenn L; Jiang B; Kubesch A; Vermehren J; Knop V; Susser S; Dietz J; Carra G; Finkelmeier F; Grammatikos G; Zeuzem S; Sarrazin C; Hildt E; Peiffer KH
    Aliment Pharmacol Ther; 2018 Jun; 47(11):1523-1535. PubMed ID: 29637585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic hepatitis B in pregnant women: is hepatitis B surface antigen quantification useful for viral load prediction?
    Fujiko M; Chalid MT; Turyadi ; Ie SI; Maghfira ; Syafri ; Wahyuni R; Roni M; Patellongi I; Massi MN; Muljono DH
    Int J Infect Dis; 2015 Dec; 41():83-9. PubMed ID: 26571304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutations in basal core promoter is associated with significant fibrosis in both HBeAg positive and negative treatment-naïve chronic hepatitis B.
    Yan LB; Zhu X; Bai L; Tang XQ; Du LY; Chen EQ; Liang LB; Tang H
    Clin Res Hepatol Gastroenterol; 2017 Jun; 41(3):296-302. PubMed ID: 27988305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Basal core promoter, precore region mutations of HBV and their association with e antigen, genotype, and severity of liver disease in patients with chronic hepatitis B in India.
    Chauhan R; Kazim SN; Bhattacharjee J; Sakhuja P; Sarin SK
    J Med Virol; 2006 Aug; 78(8):1047-54. PubMed ID: 16789012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B.
    Bayliss J; Yuen L; Rosenberg G; Wong D; Littlejohn M; Jackson K; Gaggar A; Kitrinos KM; Subramanian GM; Marcellin P; Buti M; Janssen HLA; Gane E; Sozzi V; Colledge D; Hammond R; Edwards R; Locarnini S; Thompson A; Revill PA
    Gut; 2017 Nov; 66(11):2013-2023. PubMed ID: 27534671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B.
    Sonneveld MJ; Rijckborst V; Zeuzem S; Heathcote EJ; Simon K; Senturk H; Pas SD; Hansen BE; Janssen HL
    Hepatology; 2012 Jul; 56(1):67-75. PubMed ID: 22307831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of basal core promoter and precore mutations in Chinese chronic hepatitis B patients and correlation with serum HBeAG titers.
    Qin Y; Zhang J; Mao R; Guo H; Yin Y; Wu X; Weng X; Wands J; Tong S
    J Med Virol; 2009 May; 81(5):807-14. PubMed ID: 19319958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic variability in the precore and core promoter regions of hepatitis B virus strains in Karachi.
    Abbas Z; Muzaffar R; Siddiqui A; Naqvi SA; Rizvi SA
    BMC Gastroenterol; 2006 Jul; 6():20. PubMed ID: 16863587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Precore/Core promoter variants to predict significant fibrosis in both HBeAg positive and negative chronic hepatitis B.
    Lapalus M; Laouenan C; Cardoso AC; Estrabaud E; Carvalho-Filho RJ; Zhang Q; Lada O; Appourchaux K; Mouri F; Boyer N; Bedossa P; Asselah T; Martinot-Peignoux M; Marcellin P
    Liver Int; 2015 Sep; 35(9):2082-9. PubMed ID: 25612083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High association of T1858-G1896 precore mutations with impaired base pairing and high hepatitis B virus DNA levels in HBeAg-negative chronically infected patients.
    Castelain S; Descamps V; Brochot E; Helle F; Duverlie G; Nguyen-Khac E; François C
    Arch Virol; 2017 Jul; 162(7):1913-1920. PubMed ID: 28289975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The loss of HBeAg without precore mutation results in lower HBV DNA levels and ALT levels in chronic hepatitis B virus infection.
    Kawabe N; Hashimoto S; Harata M; Nitta Y; Murao M; Nakano T; Shimazaki H; Arima Y; Komura N; Kobayashi K; Yoshioka K
    J Gastroenterol; 2009; 44(7):751-6. PubMed ID: 19430716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of hepatitis B virus (HBV) preS/S genomic variability on HBV surface antigen and HBV DNA serum levels.
    Pollicino T; Amaddeo G; Restuccia A; Raffa G; Alibrandi A; Cutroneo G; Favaloro A; Maimone S; Squadrito G; Raimondo G
    Hepatology; 2012 Aug; 56(2):434-43. PubMed ID: 22271491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations of pre-core and basal core promoter before and after hepatitis B e antigen seroconversion.
    Kamijo N; Matsumoto A; Umemura T; Shibata S; Ichikawa Y; Kimura T; Komatsu M; Tanaka E
    World J Gastroenterol; 2015 Jan; 21(2):541-8. PubMed ID: 25593470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation between the promoter basal core and precore mutations and HBsAg quantification in French blood donors infected with hepatitis B virus.
    Pivert A; Servant-Delmas A; Lunel-Fabiani F; Le Guillou-Guillemette H; Laperche S; Ducancelle A
    J Med Virol; 2015 Mar; 87(3):529-35. PubMed ID: 25170961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Precise analysis of the effect of basal core promoter/precore mutations on the main phenotype of chronic hepatitis B in mouse models.
    Liu Y; Zhao ZH; Lv XQ; Tang YW; Cao M; Xiang Q; Wu Y; Zhang HT; Lai GQ
    J Med Virol; 2020 Dec; 92(12):3412-3419. PubMed ID: 32427358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular and serological characterization of hepatitis B virus genotype A and D infected blood donors in Poland.
    Grabarczyk P; Garmiri P; Liszewski G; Doucet D; Sulkowska E; Brojer E; Allain JP;
    J Viral Hepat; 2010 Jun; 17(6):444-52. PubMed ID: 19780948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can quantitative hepatitis B surface antigen levels predict the severity of liver disease in genotype E Patients?
    Chakrabarty G; Bruce M; Horner M; Wang B; Agarwal K; Carey I
    J Viral Hepat; 2018 Jan; 25(1):80-87. PubMed ID: 28710798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Precore G1896A mutation is associated with reduced rates of HBsAg seroclearance in treated HIV hepatitis B virus co-infected patients from Western Africa.
    Boyd A; Moh R; Maylin S; Abdou Chekaraou M; Mahjoub N; Gabillard D; Anglaret X; Eholié SP; Delaugerre C; Danel C; Zoulim F; Lacombe K;
    J Viral Hepat; 2018 Oct; 25(10):1121-1131. PubMed ID: 29660214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutations in pre-core and basic core promoter regions of hepatitis B virus in chronic hepatitis B patients.
    Wang XL; Ren JP; Wang XQ; Wang XH; Yang SF; Xiong Y
    World J Gastroenterol; 2016 Mar; 22(11):3268-74. PubMed ID: 27004005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kinetics and prediction of HBsAg loss during therapy with analogues in patients affected by chronic hepatitis B HBeAg negative and genotype D.
    Boglione L; D'Avolio A; Cariti G; Gregori G; Burdino E; Baietto L; Cusato J; Ghisetti V; De Rosa FG; Di Perri G
    Liver Int; 2013 Apr; 33(4):580-5. PubMed ID: 23311449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.